Publication Feature: Brand-Brand Competition and List Prices of Brand-Name Drugs

September 2019

To better understand the interplay between new drug entry and intraclass drug prices, the authors performed a systematic review of the peer-reviewed health policy and economics literature. Among 10 identified studies evaluating a wide range of drug classes, they found no evidence that brand-brand competition lowers the list price of existing brand-name drugs within a class but did find evidence that brand-brand competition may help restrain launch list prices and be mediated by relative drug quality and marketing, with safer or more effective new drugs and greater marketing associated with higher intraclass list prices.

Read the full article by Ameet Sarpatwari, Aaron Kesselheim, and colleagues here